Fosrolapitant/Palonosetron Hydrochloride

磷罗拉匹坦/帕洛诺司琼

Report date: 2025/06/05 16:14:45
NME

Base Information

Drug NameFosrolapitant/Palonosetron Hydrochloride
Drug Alias NameHR20013 for injection磷罗拉匹坦帕洛诺司琼瑞坦宁HR-20013
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonistsSerotonin 3 (5-HT3) receptor antagonists
TargetsNeurokinin 1 receptorSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingSolid tumours
Global Approved IndicationsChemotherapy-induced nausea and vomiting
Approved Indications in ChinaChemotherapy-induced nausea and vomiting
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryMainland China
CombinationsYes FosrolapitantPalonosetron Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFujian Suncadia Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Suncadia Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsChemotherapy-induced nausea and vomitingSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A